Bruker AXS (BAXS) - 500 Beiträge pro Seite

[Luxo]

Hallo,


Bruker AXS Inc. is a worldwide developer and provider of advanced integrated x-ray systems that provide solutions for molecular and elemental analysis by x-ray diffraction and x-ray fluorescence. The Company`s products, which have particular application in the drug discovery and materials science fields, provide its customers with high-throughput capabilities to determine the structure of specific molecules, such as proteins, and to characterize and determine the composition of materials. Bruker`s integrated systems address multiple existing and emerging markets, including drug discovery and development; structural proteomics; advanced materials research, and industrial process control. The Company`s customers include biotechnology and pharmaceutical companies, semiconductor companies, raw material manufacturers, chemical companies, academic institutions and other businesses involved in materials analysis.


Gestern hat Bruker die Zahlen bekanntgegegen. Hier die Meldung:

MADISON, Wis.--(BUSINESS WIRE)--Aug. 12, 2002--Bruker AXS Inc.
(NASDAQ:BAXS), a leading global provider of advanced X-ray solutions
for the life and materials sciences, today reported its financial
results for the three- and six-month periods ended June 30, 2002.

THREE MONTHS ENDED JUNE 30, 2002

Net sales for the three months ended June 30, 2002 increased 19%
to $24.0 million, compared to $20.2 million for the three months ended
June 30, 2001. The net sales increase was primarily driven by
continued strong demand for our systems, particularly in the materials
sciences. Excluding favorable currency effects, second quarter 2002
net sales increased 15% year-over-year.
Net income for the second quarter 2002 was $0.6 million, or $0.01
per diluted share, compared to a net loss of $1.8 million, or $(0.04)
per diluted share, for the second quarter 2001. In the second quarter
of 2001, the Company recorded an IPR&D expense of $2.2 million
after-tax related to its acquisition of Nonius.
Cash and cash equivalents totaled $50.7 million as of June 30,
2002.

SIX MONTHS ENDED JUNE 30, 2002

Net sales for the six months ended June 30, 2002 increased 22% to
$47.8 million, compared to $39.1 million for the six months ended June
30, 2001. Currency effects did not significantly impact reported
revenues during this six-month period.
Net income for the first six months of 2002 was $0.9 million, or
$0.02 per diluted share, compared to a net loss of $1.6 million, or
$(0.04) per diluted share, for the comparable period in 2001.

COMMENT AND OUTLOOK

Dr. Martin Haase, President and CEO, stated: "We are again pleased
to report a successful quarter of revenue growth and operating
improvements. In addition, our new order bookings were healthy in Q2,
and our backlog remains strong. Further, we are off to a fast start in
Japan after the acquisition of MAC Science. These factors, as well as
last week`s launch of our new X8 Series of life science products,
provide improved visibility for Q3 and Q4. Therefore, we are
increasing our revenue guidance to $99 - $101 million for the year, or
revenue growth greater than 20% compared to last year."
Laura Francis, Chief Financial Officer, added: "We are pleased
that we continue to meet our revenue objectives. We also see
opportunities to accelerate the growth of our bottom-line. The rapid
expansion of our business via strong organic growth, and two
complementary acquisitions in 15 months, now allows us to focus on
productivity improvements. Therefore, we are implementing a
restructuring initiative to reduce costs and improve productivity by
eliminating redundant positions, streamlining production and reducing
operating expenses. This restructuring will result in a charge of $1.5
- $2.5 million during Q3, and subsequent annual cost savings of $2.0 -
$3.0 million."
She continued: "In addition, the Company tested goodwill with a
total value of $3.1 million for impairment pursuant to SFAS No. 142,
which will result in a non-cash goodwill impairment charge.
Accordingly, we are providing EPS guidance for the full year 2002
between $0.01 and $0.03 per share. EPS, excluding the after-tax
effects of the restructuring and goodwill impairment charges, is
expected to be $0.04 - $0.06 per share for the full year 2002. This
compares favorably to our previous EPS guidance of $0.03 per share for
the year."

Und übrigens.
Der Buchwert der Aktie liegt bei 1.5 Dollar pro Aktie!!

Also bis dann!!!
Ciao,
Luxo.

[Luxo]

Ein bisschen alt die Meldung, aber ich hatte keine Zeit die Meldung eher einzugeben.

MADISON, Wis.--(BUSINESS WIRE)--Aug. 19, 2002--Bruker AXS Inc.
(NADAQ: BAXS) today announced that its Board of Directors has
authorized the repurchase of up to 2.5 million shares of Bruker AXS
common stock. The Board of Directors views Bruker AXS` stock as
undervalued in the marketplace and it believes that the stock
repurchase program will be beneficial to Bruker AXS shareholders. Any
purchases under the Bruker AXS stock repurchase program may be made,
from time-to-time, in the open market, through block trades or
otherwise, at the discretion of company management.
---
Ciao,
Luxo.

[Luxo]

MADISON, Wis.--(BUSINESS WIRE)--Nov. 7, 2002--Bruker AXS Inc. (NASDAQ: BAXS - News), a leading global provider of advanced X-ray solutions for the life and materials sciences, today reported its financial results for the third quarter and for the nine months ended September 30, 2002.
ADVERTISEMENT


THIRD QUARTER 2002

Net sales for the three months ended September 30, 2002 increased 27% to $26.9 million, compared to $21.2 million for the three months ended September 30, 2001. The net sales increase was driven by continued strong demand for our systems, particularly in the materials research segment. Excluding favorable currency effects, third quarter 2002 net sales increased 19% year-over-year.

In the third quarter of 2002, Bruker AXS took a previously announced restructuring charge of $1.8 million before taxes, primarily for its workforce and cost reduction program. Net income for the third quarter 2002, excluding the after-tax effects of the restructuring charge, was $0.3 million, or $0.01 per diluted share, compared to a net loss of $(0.3) million, or $(0.01) per diluted share, for the third quarter 2001. On a GAAP basis, the net loss for the third quarter 2002 was $(0.8) million or $(0.01) per diluted share.

Cash and cash equivalents totaled $49.1 million as of September 30, 2002.

NINE MONTHS ENDED SEPTEMBER 30, 2002

Net sales for the nine months ended September 30, 2002 increased 24% to $74.7 million, compared to $60.2 million for the nine months ended September 30, 2001. Excluding favorable currency effects, year-to-date net sales increased 21% compared to the prior year.

As announced in the prior quarter, the Company identified the impairment of goodwill pursuant to SFAS No. 142. The Company completed the impairment tests in the third quarter, which resulted in the Company recording a non-cash goodwill impairment charge of $0.6 million after tax. In accordance with the provisions of SFAS No. 142, the impairment loss has been recorded in the first quarter of 2002 as a cumulative effect of change in accounting principle. Year-to-date net income, excluding the after-tax effects of the goodwill impairment and restructuring charges, was $1.2 million or $0.02 per diluted share, compared to a net loss of $(2.0) million or $(0.05) per diluted share in the first nine months of 2001. In the second quarter of 2001, the Company recorded an IPR&D charge of $2.1 million after-tax related to its acquisition of Nonius B.V.

On a GAAP basis, the net loss was $(0.5) million or $(0.01) per diluted share for the nine months ended September 30, 2002.

COMMENT AND OUTLOOK

Dr. Martin Haase, President and CEO, stated: "We are very pleased with our third quarter operating and financial performance. We continue to meet or exceed our goals. Our strong backlog and full sales pipeline gives us confidence in the business and good revenue visibility into Q1 2003. Therefore, we are increasing our revenue guidance to over $101 million for 2002. Since we do not believe our stock price reflects the intrinsic value of the Company, we have been steadily repurchasing our shares in the market pursuant to our previous announcement."

Laura Francis, Chief Financial Officer, added: "With revenues continuing to exceed expectations in a difficult market environment, we are now focusing on the growth of our bottom-line. We believe we will begin to see the effects of our restructuring initiatives beginning in Q4 and enter 2003 with the benefit of an improved cost position. Accordingly, we reaffirm our previous guidance for the full year 2002 of $0.01 per share. Our expectations for EPS, excluding the after-tax effects of the restructuring and goodwill impairment charges, is reaffirmed at $0.04 per share for the full year 2002."

[Luxo]

Bruker AXS Reports Record Revenues of $104.3 Million in 2002
Thursday February 27, 7:13 am ET
Revenues of $29.6 Million and Cash from Operations of $4.7 Million in the Fourth Quarter of 2002

MADISON, Wis.--(BUSINESS WIRE)--Feb. 27, 2003--Bruker AXS Inc. (NASDAQ:BAXS - News), a leading global provider of advanced X-ray solutions for life and materials sciences, today reported its financial results for the fourth quarter and year ended December 31, 2002.

ADVERTISEMENT
FOURTH QUARTER 2002

Net sales for the three months ended December 31, 2002 increased 33% to $29.6 million, compared to $22.3 million for the three months ended December 31, 2001. Excluding favorable currency effects, fourth quarter 2002 net sales increased 25% year-over-year. Gross margins continued to improve, increasing to 41.4% in the fourth quarter of 2002 compared to 39.9% in the same period in 2001. During the quarter, the Company took a special non-cash charge of $1.3 million to write-down investments in two unaffiliated proteomics companies.

On a GAAP basis, the net loss for the fourth quarter 2002 was $(0.4) million or $(0.01) per diluted share, compared to $(5.4) million or $(0.13) per diluted share for the fourth quarter 2001. Net income before special charges for the fourth quarter 2002, which excludes the non-cash write-down of investments, was $0.9 million or $0.02 per diluted share. This compares to net income before special charges of $0.2 million or $0.00 per diluted share for the fourth quarter 2001, excluding one-time non-cash charges for preferred stock accretion and beneficial conversion of $5.6 million.

Cash and cash equivalents totaled $52.7 million as of December 31, 2002. During the fourth quarter 2002, the Company generated cash from operations of $4.7 million and free cash flow of $2.9 million.

YEAR ENDED DECEMBER 31, 2002

Net sales for the year ended December 31, 2002 increased 26% to $104.3 million, compared to $82.6 million for the year 2001. Excluding favorable currency effects, 2002 net sales increased 22% compared to the prior year. The MAC Science acquisition contributed $4.7 million of net sales in 2002. The net sales increase was driven by strong demand for the Company`s systems, particularly in materials research and industrial process control. Gross margins improved for the year as well, increasing to 39.5% in 2002 from 38.2% in 2001.

On a GAAP basis, the net loss was $(0.9) million or $(0.02) per diluted share for 2002, compared to a net loss of $(7.4) million or $(0.19) per diluted share for 2001. Net income before special charges was $2.1 million or $0.04 per diluted share for 2002, compared to net income of $0.7 million or $0.02 per diluted share for 2001.

The use of "net income before special charges" and "earnings per share before special charges" in this press release refers to amounts calculated by removing certain expenses including the write-down of investments, write-down of goodwill, and restructuring costs in 2002, and in-process research and development expense, preferred stock accretion, and beneficial conversion charges for 2001. In addition, the Company computed free cash flow as cash from operations less purchases of property and equipment. These measures are not in accordance with, or an alternative for, generally accepted accounting principles and may be different from non-GAAP measures used by other companies. Except as expressly noted in this press release, all numbers are presented in accordance with U.S. GAAP.

FINANCIAL OUTLOOK FOR 2003

The Company expects to achieve continued organic revenue growth of greater than 15% on a constant currency basis in 2003. Earnings per share for the full year 2003 is expected to be in the range of $0.07 to $0.09 per diluted share.

ANALYSIS AND COMMENT

Dr. Martin Haase, President and CEO, stated: "We made a great deal of progress in 2002 that will fuel the growth of the Company in the future. We expanded and focused our global distribution organization and launched a series of products including the X8 PROTEUM and APEX lines for life science applications, the new D8 DISCOVER series with a high throughput screening system for combinatorial analysis, and the S2 Ranger table-top spectrometer for QA/QC applications. Our continued strong investment in core technologies and new product development has generated a full pipeline of new products that will be launched in 2003. Finally, we are particularly pleased with our acquisition of MAC Science, which is now opening the opportunity for our products in the Japanese market."

Laura Francis, Chief Financial Officer, added: "We are encouraged by our operating and financial performance in 2002. In our first year as a public company, we met or exceeded expectations in every quarter. The Company exhibited strong revenue growth this year, despite weakness in the overall market. The Company doubled earnings per share before special charges between 2001 and 2002. And, the Company generated significant cash from operations and free cash flow in the fourth quarter of 2002. After a period of investment, the Company is beginning to reap benefits from those investments. We believe our performance in 2002 shows that we are positioned for sustainable, profitable growth in 2003 and beyond."

EARNINGS CALL

On Thursday, February 27, 2003, the Company will host a live streaming-audio webcast of its earnings call at 2:00 p.m. Eastern time. To listen to the webcast, investors should go to www.bruker-axs.com, select Investor Relations, and then click on the Webcast registration button. Investors can also listen by telephone by calling 1-888-565-5146 in the U.S. and Canada, or 1-706-679-5344 outside of North America. Investors should refer to the conference call led by CFO Laura Francis. A toll-free replay will be available by dialing 1-800-642-1687, or 1-706-645-9291 outside the U.S., with the conference ID access code of 8326576.

The webcast is also being distributed over CCBN`s Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through CCBN`s individual investors center at www.companyboardroom.com or by visiting any of the investor sites in CCBN`s Individual Investor Network. Institutional investors can access the call via CCBN`s password-protected event management site, StreetEvents (www.streetevents.com).

About Bruker AXS

Bruker AXS is a leading worldwide developer and provider of life science and advanced materials research tools based on X-ray technology. For more information about Bruker AXS, please visit www.bruker-axs.com.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein, including the Financial Outlook for 2003, are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to product development, manufacturing, market acceptance, cost and pricing of Bruker AXS` products, dependence on collaborative partners, suppliers, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation and other risk factors discussed from time to time in Bruker AXS` reports or filings with the Securities and Exchange Commission. Bruker AXS expressly disclaims any obligations to update the information contained herein.

Bruker AXS Inc.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
(Unaudited)

Three Months Ended Year Ended
December 31, December 31,
------------------ ------------------
2002 2001 2002 2001
-------- -------- -------- --------

Net sales $ 29,604 $ 22,342 $104,290 $ 82,588
Cost of sales 17,355 13,417 63,114 51,063
-------- -------- -------- --------
Gross profit 12,249 8,925 41,176 31,525
-------- -------- -------- --------

Operating expenses:
Research and development 2,448 2,304 9,903 7,744
In-process research and
development - - - 3,590
General and administrative 2,630 1,577 8,265 5,298
Marketing and selling 6,170 4,388 21,340 16,792
Restructuring charge - - 1,767 -
-------- -------- -------- --------
Total operating expenses 11,248 8,269 41,275 33,424
-------- -------- -------- --------

Operating income (loss) 1,001 656 (99) (1,899)

Other (income) expense:
Interest income (198) (122) (785) (504)
Interest expense -
third party 168 108 477 378
Interest expense -
related party - 65 2 259
Other (income) expense (460) 396 (1,614) 314
Write-down of investments in
other companies 1,300 - 1,300 -
-------- -------- -------- --------

Income (loss) before income
taxes, minority interest in
subsidiary and cumulative
effect of change in
accounting principle 191 209 521 (2,346)
Income tax expense (benefit) 603 53 718 (969)
-------- -------- -------- --------
(Loss) income before minority
interest in subsidiary and
cumulative effect of change in
accounting principle (412) 156 (197) (1,377)
Minority interest in subsidiary 6 - 59 -
-------- -------- -------- --------
(Loss) income before cumulative
effect of change in
accounting principle (418) 156 (256) (1,377)
Cumulative effect of change in
accounting principle, net
of taxes - - (617) -
-------- -------- -------- --------
Net (loss) income (418) 156 (873) (1,377)

Convertible preferred stock
accretion - 360 - 833
Beneficial conversion feature - 5,192 - 5,192
-------- -------- -------- --------

Net loss available to common
shareholders $ (418) $ (5,396) $ (873) $ (7,402)
========= ========= ========= =========

Basic and diluted earnings (loss) per share:
(Loss) income before cumulative
effect of change in accounting
principle, net of taxes $ (0.01) $ (0.13) $ (0.01) $ (0.19)
Cumulative effect of change
in accounting principle,
net of taxes - - (0.01) -
-------- -------- -------- --------
Net loss available to common
shareholders $ (0.01) $ (0.13) $ (0.02) $ (0.19)
========= ========= ========= =========

Weighted average shares
outstanding - basic 55,773 42,109 56,028 39,613
Weighted average shares
outstanding - diluted 55,887 42,109 56,216 39,613



Bruker AXS Inc.
RECONCILIATION FROM GAAP NET LOSS TO NET INCOME BEFORE SPECIAL CHARGES
(in thousands, except per share data)
(Unaudited)

Three Months Ended Year Ended
December 31, December 31,
------------------ -------------------
2002 2001 2002 2001
-------- -------- -------- --------

GAAP net loss $ (418) $ (5,396) $ (873) $ (7,402)

Adjustments, net of tax:
In-process research and
development 2,118
Restructuring charge 1,071
Write-down of investments in
other companies 1,300 1,300
Cumulative effect
(write-down of goodwill) 617
Convertible preferred stock
accretion 360 833
Beneficial conversion feature 5,192 5,192
-------- -------- -------- --------

Net income before special
charges $ 882 $ 156 $ 2,115 $ 741
======== ======== ======== ========

Earnings per share before
special charges $ 0.02 $ 0.00 $ 0.04 $ 0.02
======== ======== ======== ========

Weighted average shares
outstanding - diluted 55,887 42,109 56,216 39,613


Net income before special charges presented above is used by the
Company to measure performance against prior periods and is not in
accordance with generally accepted accounting principles. The above
reconciliation identifies those activities and transactions excluded
by management. The Company believes these activities or transactions
may not be indicative of understanding the performance of the business
or its future results.


Bruker AXS Inc.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except per share data)
(Unaudited)

December 31,
2002 2001
-------- --------
ASSETS
Current assets:
Cash and cash equivalents $ 52,651 $ 48,787
Accounts receivable, net 20,803 17,207
Inventories 34,130 26,769
Prepaid expenses 1,028 809
Other current assets 876 952
Deferred income taxes 1,601 886
-------- --------

Total current assets 111,089 95,410

Property and equipment, net 20,706 8,151
Restricted cash 128 108
Goodwill, net 3,093 3,099
Intangible assets-trademarks and tradenames, net 250 250
Investments in other companies 700 2,000
Other assets 756 1,054
Deferred income taxes 2,329 2,018
-------- --------

Total assets $139,051 $112,090
======== ========

LIABILITIES AND SHAREHOLDERS` EQUITY
Current liabilities:
Short-term borrowings $ 1,813 $ 242
Current portion of long-term debt 726 -
Related party debt - current - 229
Accounts payable 11,073 7,416
Other current liabilities 24,587 20,901
-------- --------

Total current liabilities 38,199 28,788

Other long-term liabilities 517 95
Long-term debt 9,834 2,200
Accrued pension 4,858 3,437
Minority interest in consolidated subsidiary 80 -

Shareholders` equity:
Preferred stock, $.01 par value, 5,000,000
authorized, none issued and outstanding at
December 31, 2002 and 2001 - -
Common stock, $.01 par value, 100,000,000
shares authorized, 56,180,338 and 54,830,338
shares issued at December 31, 2002 and 2001,
respectively 562 548
Additional paid-in capital 87,169 79,135
Accumulated deficit (2,448) (1,575)
Treasury stock, at cost, 457,700 shares and
0 shares at December 31, 2002 and 2001,
respectively (1,096) 0
Accumulated other comprehensive income (loss) 1,376 (538)
--------- ---------
Total shareholders` equity 85,563 77,570
--------- ---------

Total liabilities and shareholders` equity $139,051 $112,090
========= =========



Contact:

Bruker AXS Inc.
Chief Financial Officer
Laura Francis, 608/276-3000
[e-mail]


Source: Bruker AXS Inc.